Incidence and predictors of chronic kidney diseases among type 2 diabetes mellitus patients at St. Paul ’s Hospital, Addis Ababa, Ethiopia

This study aimed to estimate the incidence of chronic kidney disease and its predictors among newly diagnosed type 2 diabetes patients attending St. Paul ’s Hospital, Addis Ababa, Ethiopia.
Source: BMC Research Notes - Category: Research Authors: Tags: Research note Source Type: research

Related Links:

Victorine B Nzana, Anusha Rohit, Deepu George, Madhusudan Vijayan, Milly Mathew, Sundar Sankaran, Palaniappan Nagarajan, Georgi AbrahamIndian Journal of Medical Microbiology 2018 36(2):282-284A 51-year-old female, with non-alcoholic liver cirrhosis, portal hypertension, type 2 diabetes mellitus, autosomal dominant polycystic kidney disease with a clipped cerebral aneurysm and chronic kidney disease stage 5 was on continuous ambulatory peritoneal dialysis (CAPD) for 6.5 years elsewhere. She came for opinion on continuation of CAPD as she had 21 episodes of peritonitis in 76 months. Her blood pressure was 80/50 mmHg. She was...
Source: Indian Journal of Medical Microbiology - Category: Microbiology Authors: Source Type: research
Publication date: Available online 1 August 2018Source: Alexandria Journal of MedicineAuthor(s): Richard K.D. Ephraim, Richard Mantey, Stephen Atombo, Samuel A. Sakyi, Linda A. Fondjo, Worlanyo Tashie, Hope Agbodzakey, Felix A. Botchway, Bright AmankwaaAbstractBackgroundChronic kidney disease (CKD), has become a public health concern as it has been reported to cause adverse outcomes such as kidney failure and premature death. This cross sectional study compared the Kidney Disease: Improving Global Outcomes (KDIGO) and Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines in assessing the prevalence of CKD in Type 2...
Source: Alexandria Journal of Medicine - Category: General Medicine Source Type: research
Authors: Lajara R Abstract Chronic kidney disease (CKD) and type 2 diabetes mellitus (T2D) frequently coexist and are associated with poor clinical outcomes. Dipeptidyl peptidase-4 (DPP-4) inhibitors can be used for patients with T2D and CKD, and preclinical evidence suggests these agents may slow the progression of kidney disease in T2D. Although clinical evidence of the renal effects of DPP-4 inhibitors is limited, the recent publication of the MARLINA-T2D study provided important new data. In MARLINA-T2D, linagliptin was associated with significant improvements in glycemic control with a non-significant reductio...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
Publication date: August–September 2018Source: Revista Clínica Española (English Edition), Volume 218, Issue 6Author(s): J. Carretero Gómez, J.C. Arévalo LoridoAbstractDiabetes mellitus type 2 is the main cause of chronic kidney disease. Patients with this disease have higher morbidity and mortality and risk of hypoglycaemia than those without this disease. In 2010, type 2 diabetes was the reason for starting renal replacement therapy in 24.7% of patients. The prevalence of microalbuminuria, proteinuria and a reduced glomerular filtration rate is 36%, 8% and 22%, respectively. The presence...
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
Conclusions: Key TCA cycle metabolites, especially fumarate, may be involved in pathophysiologic pathway independent of traditional cardio- renal risk factors leading to CKD progression in patients with T2DM. PMID: 30060124 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
Publication date: Available online 24 July 2018Source: Molecular Genetics and MetabolismAuthor(s): Meryl Waldman, Joan C. Han, Daniela P. Reyes-Capo, Joy Bryant, Kathryn A. Carson, Baris Turkbey, Peter Choyke, Jürgen K. Naggert, William A. Gahl, Jan D. Marshall, Meral Gunay-AygunAbstractAlström Syndrome is a ciliopathy associated with obesity, insulin resistance/type 2 diabetes mellitus, cardiomyopathy, retinal degeneration, hearing loss, progressive liver and kidney disease, and normal cognitive function. ALMS1, the protein defective in this disorder, localizes to the cytoskeleton, microtubule organizing center,...
Source: Molecular Genetics and Metabolism - Category: Genetics & Stem Cells Source Type: research
Publication date: Available online 3 November 2017Source: Clinica Chimica ActaAuthor(s): Sahapab Anuwatmatee, Shudi Tang, Ben J. Wu, Kerry-Anne Rye, Kwok Leung OngAbstractThe association between fibroblast growth factor 21 (FGF21) and kidney function has been extensively studied in recent years in both animal and human studies. However, the exact functional role of FGF21 in the kidney remains unclear. Previous animal studies have shown that administration of FGF21 ameliorates kidney function, morphological glomerular abnormalities, dyslipidemia, hyperglycemia, insulin resistance, oxidative stress and obesity. In human stud...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
Conclusions: CD146 is associated with kidney injury and could be a good marker to predict renal outcomes in patients with early stages of DN.Cell Physiol Biochem 2018;48:63 –74
Source: Cellular Physiology and Biochemistry - Category: Cytology Source Type: research
Publication date: March 2018Source: Advances in Chronic Kidney Disease, Volume 25, Issue 2Author(s): Vikram Patney, Kunal Chaudhary, Adam Whaley-ConnellThe global incidence and prevalence of diabetes continues to expand due primarily to the influences of obesity and the contribution of obesity to the progression of type 2 diabetes mellitus. The rising prevalence of type 2 diabetes has driven an increase in rates of CKD in the past 3 decades in the United States. In turn, so have the rates for complications related to type 2 diabetes including CKD, eg, diabetic kidney disease (DKD). Although incident rates for DKD have stab...
Source: Advances in Chronic Kidney Disease - Category: Urology & Nephrology Source Type: research
Publication date: July 2018Source: The Lancet Diabetes &Endocrinology, Volume 6, Issue 7Author(s): Srinivasan Beddhu, Tom Greene, Robert Boucher, William C Cushman, Guo Wei, Gregory Stoddard, Joachim H Ix, Michel Chonchol, Holly Kramer, Alfred K Cheung, Paul L Kimmel, Paul K Whelton, Glenn M ChertowSummaryBackgroundGuidelines, including the 2017 American College of Cardiology and American Heart Association blood pressure guideline, recommend tighter control of systolic blood pressure in people with type 2 diabetes. However, it is unclear whether intensive lowering of systolic blood pressure increases the incidence of c...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
More News: Chronic Kidney Disease | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Ethiopia Health | Hospitals | Research | Study | Urology & Nephrology